SIHUAN PHARM (00460.HK): Dongyan skin booster gets five new specs in China
- The five newly approved specifications are 0.75mL/tube, 1.25mL/tube, 1.75mL/tube, 2.25mL/tube and 2.75mL/tube; the previously approved seven comprise 0.5mL/tube, 1.0mL/tube, 1.5mL/tube, 2.0mL/tube, 2.5mL/tube, 3.0mL/tube and 5mL/box.
- Dongyan is China's first composite solution skin booster containing L-carnosine for direct facial use, with core ingredients including hyaluronic acid, L-carnosine, various amino acids and vitamin B2, injected into the dermis layer.
NewTimeSpace News: On 5 October 2026, Sihuan Pharmaceutical Holdings Group Ltd. (stock code: 00460) announced that five new specifications of the Hyaluronic Acid Sodium Composite Solution for Injection (brand name: Dongyan), independently developed by Meiyan Space Biotechnology (Jilin) Co., Ltd., a subsidiary of the Group, have been approved for launch by the National Medical Products Administration of China (the "NMPA").
The announcement disclosed that Dongyan is the first composite solution skin booster containing L-carnosine approved in China for direct facial use. Its core ingredients include hyaluronic acid, L-carnosine, various amino acids and vitamin B2, with multiple effects such as hydrating and moisturising, antioxidant, anti-glycation, anti-inflammatory and promoting collagen regeneration, and it is used for injection into the dermis layer of the face. The five newly approved specifications are 0.75mL/tube, 1.25mL/tube, 1.75mL/tube, 2.25mL/tube and 2.75mL/tube, while the previously approved specifications comprise 0.5mL/tube, 1.0mL/tube, 1.5mL/tube, 2.0mL/tube, 2.5mL/tube, 3.0mL/tube and 5mL/box (containing two 2.5mL/tube products), making a total of seven.
The announcement stated that the specification expansion fills the gap in the original product dosage range and can be adapted to clinical scenarios such as superficial care for delicate local areas, basic full-face treatment and combined regeneration filling therapy. Meiyan Space is a "one-stop" medical aesthetics platform incubated by Sihuan Pharmaceutical, with more than 60 products in its pipeline, and its sales network covers over 370 cities and more than 9,000 medical aesthetics institutions across China.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SIHUAN PHARM (00460.HK): Five New Specifications of Skin Booster Dongyan Approved for Marketing by NMPA
- SIHUAN PHARM (00460.HK): Repurchases 10 million shares for about HKD 8.111 million; H1 net profit up 221% year on year
- SIHUAN PHARM(00460.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 224.7 million, YoY increase of 119%
- SIHUAN PHARM (00460.HK): Miao Guili resigns as executive director and CFO, Che Yuxuan appointed non-executive director and Song Xiaomi appointed CFO
- SIHUAN PHARM(00460.HK): First Patient Dosed in Phase III Trial of Anaprazole Sodium from Xuanzhu Biologics for Helicobacter Pylori Eradication
